Supercharged CAR t cells take on tough lymphoma

NCT ID NCT05989204

Ongoing Disease control Sponsor: University of Pennsylvania Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase trial is testing a new type of immune cell therapy called TmCD19-IL18 CAR T cells in people with a blood cancer (non-Hodgkin lymphoma) that has come back or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them to better recognize and attack cancer cells, and giving them back. The main goals are to find the safest dose and see if it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TmCD19-IL18 CAR T cells (a type of immune cell therapy that targets CD19 and releases IL-18 to boost the immune response)
What this could lead to: If successful, this could lead to a more effective treatment for certain blood cancers that have not responded to standard therapies.
What could go wrong: This is an early Phase 1 trial with only 24 participants, so it is too soon to know if it will work. There are risks of serious side effects, including cytokine release syndrome and neurological issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-HODGKIN LYMPHOMA

Contacts and locations

Locations

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.